Feb 7 (Reuters) - Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.
Advertisement
(Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
